San Francisco Myeloma Rounds
Pre & Post-Assessment
This activity is provided by The Leukemia & Lymphoma Society and Medical Learning Institute Inc, in collaboration with the Association of Cancer Care Centers™ (ACCC).
Please enable JavaScript in your browser to complete this form.
-
Step
1
of 2
Name
*
First
Last
Email
*
Pre-Assessment Responses
1. The IMROZ trial demonstrated that, at ~5-year follow-up, adding Isatuximab to VRd in transplant-ineligible myeloma significantly improved:
A) Median Overall Survival
B) Median Progression-Free Survival
C) Treatment-related Toxicity Profiles
D) Peripheral Neuropathy incidence rates
2. In the context of transplant-eligible patients, recent trials such as ISKIA and PERSEUS demonstrate that adding a CD38 antibody (Daratumumab or Isatuximab) to standard induction regimens (VRd or KRd) significantly improves which outcome measure post-consolidation?
A) Overall Survival (OS) at 1 year
B) Incidence of grade ≥3 peripheral neuropathy
C) Minimal Residual Disease (MRD) negativity rates
D) Incidence of cardiac toxicity
3. A 55-year-old woman with history of IgG Kappa multiple myeloma presents for routine follow up after completing induction chemotherapy with DRVd followed by autologous stem cell transplant one year prior. Today, her M-protein is measurable at 1.5 g/dL. Hemoglobin is stable at 10.6 g/dL, creatinine is at baseline 1 mg/dL, and Ca is 9.8 mg/dL. You would like to refer her for anti-BCMA CAR T-cell therapy. Which statement best describes the role of further targeted/immuno-therapy?
A) Bridging therapy is unnecessary if early referral to CAR T-cell therapy is arranged.
B) Bridging therapy should be avoided to prevent further immunosuppression and antigen down-regulation.
C) Bridging therapy is important to allow time for manufacturing of the CAR T product as well as provide improved disease control, which has been associated with lower rates of CAR T- associated toxicity.
D) Bridging therapy is necessary because anti-BCMA CAR T-cell therapy is only effective when patients are in complete remission.
4. Anitocaptagene autoleucel (anito-cel) is a promising new CAR T-cell therapy being studied in relapsed/refractory multiple myeloma. What is unique about this CAR T-cell product in multiple myeloma?
A) It utilizes a 4-1BB costimulatory domain
B) It utilizes a novel and compact D-Domain binder
C) It is an allogeneic CAR T-cell product
D) It targets G protein-coupled receptor class C group 5 member D (GPRC5D)
5. In patients relapsing after BCMA-directed CAR-T cell therapy, which is true:
A) GPRC5D directed bispecific antibodies are more effective and BCMA directed monocalonal antibodies
B) Talquetamab and Elranatamab included prior-BCMA directed therapies in their trials, showing comparable outcomes to the BCAM-naive cohorts
C) Infectious toxicity of bispecifics is worse in patients who have received prior CAR-T cell therapy
Next
Post-Assessment Responses
1. The IMROZ trial demonstrated that, at ~5-year follow-up, adding Isatuximab to VRd in transplant-ineligible myeloma significantly improved:
A) Median Overall Survival
B) Median Progression-Free Survival
C) Treatment-related Toxicity Profiles
D) Peripheral Neuropathy incidence rates
2. In the context of transplant-eligible patients, recent trials such as ISKIA and PERSEUS demonstrate that adding a CD38 antibody (Daratumumab or Isatuximab) to standard induction regimens (VRd or KRd) significantly improves which outcome measure post-consolidation?
A) Overall Survival (OS) at 1 year
B) Incidence of grade ≥3 peripheral neuropathy
C) Minimal Residual Disease (MRD) negativity rates
D) Incidence of cardiac toxicity
3. A 55-year-old woman with history of IgG Kappa multiple myeloma presents for routine follow up after completing induction chemotherapy with DRVd followed by autologous stem cell transplant one year prior. Today, her M-protein is measurable at 1.5 g/dL. Hemoglobin is stable at 10.6 g/dL, creatinine is at baseline 1 mg/dL, and Ca is 9.8 mg/dL. You would like to refer her for anti-BCMA CAR T-cell therapy. Which statement best describes the role of further targeted/immuno-therapy?
A) Bridging therapy is unnecessary if early referral to CAR T-cell therapy is arranged.
B) Bridging therapy should be avoided to prevent further immunosuppression and antigen down-regulation.
C) Bridging therapy is important to allow time for manufacturing of the CAR T product as well as provide improved disease control, which has been associated with lower rates of CAR T- associated toxicity.
D) Bridging therapy is necessary because anti-BCMA CAR T-cell therapy is only effective when patients are in complete remission.
4. Anitocaptagene autoleucel (anito-cel) is a promising new CAR T-cell therapy being studied in relapsed/refractory multiple myeloma. What is unique about this CAR T-cell product in multiple myeloma?
A) It utilizes a 4-1BB costimulatory domain
B) It utilizes a novel and compact D-Domain binder
C) It is an allogeneic CAR T-cell product
D) It targets G protein-coupled receptor class C group 5 member D (GPRC5D)
5. In patients relapsing after BCMA-directed CAR-T cell therapy, which is true:
A) GPRC5D directed bispecific antibodies are more effective and BCMA directed monocalonal antibodies
B) Talquetamab and Elranatamab included prior-BCMA directed therapies in their trials, showing comparable outcomes to the BCAM-naive cohorts
C) Infectious toxicity of bispecifics is worse in patients who have received prior CAR-T cell therapy
Submit
Scroll to Top
